4.720USD+0.21%Mkt Cap: 12.76M USDP/E: —Last update: 2026-05-26
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead produc…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap12.76M USD
Enterprise Value2.59M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.61M USD
Revenue/Share—
Last Price4.720 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.74
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.00
EPS (TTM)-4.01
EPS (Forward)-2.70
52W Range
4.5001% of range43.50
52W High43.50 USD
52W Low4.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-97.73%
ROA-82.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.23M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-41.30%
Net Debt-10.14M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio4.86
Quick Ratio4.57
Book Value/Sh4.704 USD
Cash/Share3.790 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateFeb 19, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)24.80 USD
Target Range12.00 USD – 32.00 USD
# Analysts5
Ownership
Shares Out.2.70M
Float2.47M
Insiders4.55%
Institutions6.19%
Short Interest
Short Ratio2.5d
Short % Float2.89%
Short % Out.2.75%
Shares Short72.90K
Short (prev mo.)61.08K
Technical
SMA 505.483 (-13.9%)
SMA 2007.988 (-40.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)29.16K
Avg Vol (10d)22.91K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—